What is Procept Biorobotics Corp's earnings per share (EPS)?

Procept Biorobotics Corp (PRCT) reported diluted earnings per share of $-1.72 for fiscal year 2025. This represents a 1.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Procept Biorobotics Corp Financials

PRCT

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Procept Biorobotics Corp (PRCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PRCT FY2025 2026-04-30

Scale is improving unit economics, but commercial spending still outruns gross profit, keeping this fast-growing business cash-consuming.

Between FY2024 and FY2025, operating cash burn improved from -$99.2M to -$49.0M. That happened even though operating loss remained about -$100M and capex climbed to $9.4M, a sign that cash conversion is improving as scale rises.

The core product is becoming structurally more attractive: gross margin expanded from 52.2% in FY2023 to 63.7% in FY2025. Operating margin also improved to -33.7%, but SG&A still exceeded gross profit, so growth is covering more overhead without yet paying for the sales machine.

The balance sheet still reflects a business funded mainly by earlier equity raises rather than rising leverage: cash ended FY2025 at $286.5M while long-term debt stayed near $51.6M. With financing inflow dropping to $11.2M from $180.1M, the latest expansion leaned less on new capital and more on a smaller burn rate.

Financial Health Signals

Financial Profile 52/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Procept Biorobotics Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Procept Biorobotics Corp has an operating margin of -33.7%, meaning the company retains $-34 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -43.0% the prior year.

Growth

100

Procept Biorobotics Corp's revenue surged 37.2% year-over-year to $308.1M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Procept Biorobotics Corp carries a low D/E ratio of 0.14, meaning only $0.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 6.85, Procept Biorobotics Corp holds $6.85 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Procept Biorobotics Corp generated -$49.0M in operating cash flow, capex of $9.4M consumed most of it, leaving -$58.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Procept Biorobotics Corp generates a -0.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 11/100. This is up from -0.0% the prior year.

Piotroski F-Score Weak

2/9

Procept Biorobotics Corp passes 2 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

512.55x

For every $1 of reported earnings, Procept Biorobotics Corp generates $512.55 in operating cash flow (-$49.0M OCF vs -$96K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-29.0x

Procept Biorobotics Corp earns $-29.0 in operating income for every $1 of interest expense (-$103.9M vs $3.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$308.1M

YoY+37.2%

5Y CAGR+109.0%

Procept Biorobotics Corp generated $308.1M in revenue in fiscal year 2025. This represents an increase of 37.2% from the prior year.

EBITDA

-$97.5M

YoY-6.7%

Procept Biorobotics Corp's EBITDA was -$97.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 6.7% from the prior year.

Net Income

-$96K

YoY-4.5%

Procept Biorobotics Corp reported -$96K in net income in fiscal year 2025. This represents a decrease of 4.5% from the prior year.

EPS (Diluted)

$-1.72

YoY+1.7%

Procept Biorobotics Corp earned $-1.72 per diluted share (EPS) in fiscal year 2025. This represents an increase of 1.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$58.3M

YoY+43.7%

Procept Biorobotics Corp generated -$58.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 43.7% from the prior year.

Cash & Debt

$286.5M

YoY-14.1%

5Y CAGR+23.4%

Procept Biorobotics Corp held $286.5M in cash against $51.6M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

56M

YoY+2.9%

5Y CAGR+64.2%

Procept Biorobotics Corp had 56M shares outstanding in fiscal year 2025. This represents an increase of 2.9% from the prior year.

Margins & Returns

Gross Margin

63.7%

YoY+2.6pp

5Y CAGR+80.0pp

Procept Biorobotics Corp's gross margin was 63.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.6 percentage points from the prior year.

Operating Margin

-33.7%

YoY+9.3pp

5Y CAGR+585.7pp

Procept Biorobotics Corp's operating margin was -33.7% in fiscal year 2025, reflecting core business profitability. This is up 9.3 percentage points from the prior year.

Net Margin

-0.0%

YoY+0.0pp

5Y CAGR+687.0pp

Procept Biorobotics Corp's net profit margin was -0.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.0 percentage points from the prior year.

Return on Equity

-0.0%

YoY-0.0pp

Procept Biorobotics Corp's ROE was -0.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$71.3M

YoY+14.4%

5Y CAGR+34.4%

Procept Biorobotics Corp invested $71.3M in research and development in fiscal year 2025. This represents an increase of 14.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$9.4M

YoY+112.2%

5Y CAGR+109.3%

Procept Biorobotics Corp invested $9.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 112.2% from the prior year.

PRCT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$308.1M+37.2%	$224.5M+64.8%	$136.2M+81.6%	$75.0M+117.6%	$34.5M+346.7%	$7.7M
Cost of Revenue	$111.8M+28.0%	$87.4M+34.2%	$65.1M+71.7%	$37.9M+103.8%	$18.6M+107.4%	$9.0M
Gross Profit	$196.2M+43.1%	$137.1M+93.0%	$71.0M+91.6%	$37.1M+133.8%	$15.9M+1364.1%	-$1.3M
R&D Expenses	$71.3M+14.4%	$62.3M+28.6%	$48.4M+67.2%	$29.0M+52.6%	$19.0M+16.7%	$16.3M
SG&A Expenses	$228.8M+33.5%	$171.4M+30.1%	$131.8M+48.3%	$88.8M+74.0%	$51.0M+68.6%	$30.3M
Operating Income	-$103.9M-7.5%	-$96.6M+11.5%	-$109.2M-35.2%	-$80.7M-49.0%	-$54.2M-13.3%	-$47.8M
Interest Expense	$3.6M-14.3%	$4.2M+4.7%	$4.0M-22.9%	$5.2M-10.8%	$5.8M+10.4%	$5.3M
Income Tax	$190K-48.4%	$368K+360.0%	$80K	$0	$0	$0
Net Income	-$96K-4.5%	-$91K+13.7%	-$106K-21.5%	-$87K-45.6%	-$60K+99.9%	-$53.0M
EPS (Diluted)	$-1.72+1.7%	$-1.75+21.9%	$-2.24-14.3%	$-1.96+46.0%	$-3.63+74.9%	$-14.47

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$83.1M+8.8%	$76.4M-8.3%	$83.3M+5.2%	$79.2M+14.5%	$69.2M+1.4%	$68.2M+16.9%	$58.4M+9.4%	$53.4M
Cost of Revenue	$29.2M-2.9%	$30.1M+2.6%	$29.3M+6.9%	$27.4M+9.7%	$25.0M+1.8%	$24.6M+14.5%	$21.5M-1.9%	$21.9M
Gross Profit	$53.9M+16.5%	$46.3M-14.2%	$54.0M+4.4%	$51.7M+17.2%	$44.2M+1.1%	$43.7M+18.3%	$36.9M+17.2%	$31.5M
R&D Expenses	$21.5M+12.6%	$19.1M+4.8%	$18.2M+3.1%	$17.6M+7.5%	$16.4M+8.9%	$15.1M-9.5%	$16.6M-4.9%	$17.5M
SG&A Expenses	$65.1M+11.6%	$58.3M-1.2%	$59.0M+4.8%	$56.3M+2.0%	$55.2M+14.2%	$48.3M+13.2%	$42.7M+4.6%	$40.8M
Operating Income	-$32.6M-5.0%	-$31.0M-33.8%	-$23.2M-4.5%	-$22.2M+19.1%	-$27.4M-39.2%	-$19.7M+12.1%	-$22.4M+16.4%	-$26.8M
Interest Expense	$818K-8.6%	$895K-2.6%	$919K+2.7%	$895K+2.1%	$877K-9.5%	$969K-15.0%	$1.1M+10.7%	$1.0M
Income Tax	-$43K	N/A	N/A	N/A	-$47K	N/A	N/A	N/A
Net Income	-$31.6M-148.2%	$65.6M+406.5%	-$21.4M-9.4%	-$19.6M+20.9%	-$24.7M-134.1%	$72.5M+445.5%	-$21.0M+18.2%	-$25.6M
EPS (Diluted)	$-0.56	N/A	$-0.38-8.6%	$-0.35+22.2%	$-0.45	N/A	$-0.40+20.0%	$-0.50

PRCT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$508.1M-4.9%	$534.0M+31.9%	$404.7M+30.8%	$309.3M-8.2%	$337.0M+167.5%	$126.0M
Current Assets	$450.4M-6.5%	$481.8M+37.4%	$350.6M+28.6%	$272.6M-16.4%	$326.2M+195.8%	$110.3M
Cash & Equivalents	$286.5M-14.1%	$333.7M+29.7%	$257.2M+15.9%	$221.9M-27.1%	$304.3M+203.9%	$100.1M
Inventory	$70.7M+25.9%	$56.2M+41.3%	$39.8M+39.3%	$28.5M+117.1%	$13.1M+89.9%	$6.9M
Accounts Receivable	$83.5M0.0%	$83.5M+72.6%	$48.4M+216.8%	$15.3M+242.1%	$4.5M+188.2%	$1.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$142.2M+7.9%	$131.8M+6.3%	$124.0M+10.4%	$112.3M+60.5%	$69.9M-77.4%	$308.9M
Current Liabilities	$65.8M+23.8%	$53.1M+15.7%	$45.9M+30.1%	$35.3M+117.3%	$16.2M+11.8%	$14.5M
Long-Term Debt	$51.6M+0.3%	$51.5M+0.3%	$51.3M+0.2%	$51.2M+2.4%	$50.0M+12.6%	$44.4M
Total Equity	$365.9M-9.0%	$402.2M+43.3%	$280.8M+42.5%	$197.1M-26.2%	$267.1M+246.0%	-$182.9M
Retained Earnings	-$641.6M-17.5%	-$546.0M-20.1%	-$454.6M-30.4%	-$348.7M-33.3%	-$261.5M-29.7%	-$201.7M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$487.1M-4.1%	$508.1M-0.7%	$511.5M-0.3%	$513.1M-1.2%	$519.4M-2.7%	$534.0M+42.7%	$374.1M-0.1%	$374.4M
Current Assets	$428.0M-5.0%	$450.4M-1.0%	$454.8M-0.7%	$458.1M-1.7%	$465.8M-3.3%	$481.8M+49.2%	$323.0M+0.3%	$321.9M
Cash & Equivalents	$245.6M-14.3%	$286.5M-2.6%	$294.3M-2.8%	$302.7M-4.3%	$316.2M-5.2%	$333.7M+69.6%	$196.8M-8.1%	$214.1M
Inventory	$77.5M+9.7%	$70.7M+6.0%	$66.7M-0.5%	$67.0M+7.5%	$62.3M+11.0%	$56.2M+10.5%	$50.9M+15.9%	$43.9M
Accounts Receivable	$96.4M+15.4%	$83.5M-1.1%	$84.5M+4.6%	$80.8M+2.0%	$79.3M-5.1%	$83.5M+20.9%	$69.0M+17.2%	$58.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$139.4M-2.0%	$142.2M+8.3%	$131.3M+3.1%	$127.3M-2.3%	$130.2M-1.2%	$131.8M-0.8%	$132.9M+8.4%	$122.6M
Current Liabilities	$63.6M-3.3%	$65.8M+22.1%	$53.9M+8.4%	$49.7M-4.5%	$52.1M-2.0%	$53.1M-1.0%	$53.6M+25.2%	$42.8M
Long-Term Debt	$51.7M+0.1%	$51.6M+0.1%	$51.6M+0.1%	$51.5M+0.1%	$51.5M+0.1%	$51.5M+0.1%	$51.4M+0.1%	$51.4M
Total Equity	$347.7M-5.0%	$365.9M-3.8%	$380.3M-1.4%	$385.8M-0.9%	$389.2M-3.2%	$402.2M+66.7%	$241.2M-4.2%	$251.8M
Retained Earnings	-$673.2M-4.9%	-$641.6M-4.9%	-$611.7M-3.6%	-$590.3M-3.4%	-$570.7M-4.5%	-$546.0M-3.6%	-$527.1M-4.1%	-$506.2M

PRCT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$49.0M+50.6%	-$99.2M+8.1%	-$108.0M-34.4%	-$80.4M-40.2%	-$57.3M-18.6%	-$48.3M
Capital Expenditures	$9.4M+112.2%	$4.4M-82.5%	$25.2M+850.1%	$2.7M+348.1%	$592K+154.1%	$233K
Free Cash Flow	-$58.3M+43.7%	-$103.6M+22.2%	-$133.2M-60.4%	-$83.0M-43.3%	-$57.9M-19.2%	-$48.6M
Investing Cash Flow	-$9.4M-112.2%	-$4.4M+82.5%	-$25.2M-850.1%	-$2.7M-348.1%	-$592K-154.1%	-$233K
Financing Cash Flow	$11.2M-93.8%	$180.1M+7.3%	$167.8M+4545.5%	$3.6M-98.6%	$262.1M+145.5%	$106.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$38.1M-269.2%	-$10.3M-55.6%	-$6.6M+55.9%	-$15.0M+11.4%	-$17.0M+47.6%	-$32.4M-72.3%	-$18.8M-19.5%	-$15.7M
Capital Expenditures	$2.9M+57.5%	$1.9M-35.5%	$2.9M+2.4%	$2.8M+52.6%	$1.8M+56.4%	$1.2M+377.2%	$246K-76.4%	$1.0M
Free Cash Flow	-$41.0M-237.0%	-$12.2M-28.1%	-$9.5M+46.7%	-$17.8M+5.2%	-$18.8M+43.9%	-$33.6M-76.2%	-$19.0M-13.5%	-$16.8M
Investing Cash Flow	-$2.9M-57.5%	-$1.9M+35.5%	-$2.9M-2.4%	-$2.8M-52.6%	-$1.8M-56.4%	-$1.2M-377.2%	-$246K+76.4%	-$1.0M
Financing Cash Flow	$222K-95.0%	$4.4M+312.3%	$1.1M-75.4%	$4.4M+237.3%	$1.3M-99.2%	$170.5M+9843.3%	$1.7M-67.6%	$5.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PRCT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	63.7%+2.6pp	61.1%+8.9pp	52.2%+2.7pp	49.4%+3.4pp	46.0%+62.3pp	-16.3%
Operating Margin	-33.7%+9.3pp	-43.0%+37.1pp	-80.2%+27.5pp	-107.6%+49.5pp	-157.1%+462.3pp	-619.4%
Net Margin	-0.0%+0.0pp	-0.0%+0.0pp	-0.1%+0.0pp	-0.1%+0.1pp	-0.2%+686.9pp	-687.0%
Return on Equity	-0.0%0.0pp	-0.0%+0.0pp	-0.0%0.0pp	-0.0%-0.0pp	-0.0%	N/A
Return on Assets	-0.0%0.0pp	-0.0%0.0pp	-0.0%0.0pp	-0.0%0.0pp	-0.0%+42.1pp	-42.1%
Current Ratio	6.85-2.2	9.07+1.4	7.63-0.1	7.73-12.4	20.08+12.5	7.59
Debt-to-Equity	0.14+0.0	0.13-0.1	0.18-0.1	0.26+0.1	0.19+0.4	-0.24
FCF Margin	-18.9%+27.2pp	-46.2%+51.6pp	-97.8%+12.9pp	-110.7%+57.3pp	-168.0%+461.4pp	-629.5%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	64.9%+4.3pp	60.6%-4.2pp	64.8%-0.5pp	65.3%+1.5pp	63.8%-0.2pp	64.0%+0.8pp	63.2%+4.2pp	59.0%
Operating Margin	-39.2%+1.4pp	-40.6%-12.8pp	-27.8%+0.2pp	-28.0%+11.6pp	-39.7%-10.8pp	-28.9%+9.5pp	-38.4%+11.9pp	-50.3%
Net Margin	-38.1%-124.0pp	85.9%+111.6pp	-25.7%-1.0pp	-24.7%+11.0pp	-35.8%-142.0pp	106.2%+142.1pp	-35.9%+12.1pp	-48.0%
Return on Equity	-9.1%-27.0pp	17.9%+23.6pp	-5.6%-0.6pp	-5.1%+1.3pp	-6.4%-24.4pp	18.0%+26.7pp	-8.7%+1.5pp	-10.2%
Return on Assets	-6.5%-19.4pp	12.9%+17.1pp	-4.2%-0.4pp	-3.8%+0.9pp	-4.8%-18.3pp	13.6%+19.2pp	-5.6%+1.2pp	-6.9%
Current Ratio	6.73-0.1	6.85-1.6	8.44-0.8	9.21+0.3	8.95-0.1	9.07+3.0	6.02-1.5	7.51
Debt-to-Equity	0.150.0	0.140.0	0.140.0	0.130.0	0.130.0	0.13-0.1	0.210.0	0.20
FCF Margin	-49.4%-33.4pp	-15.9%-4.5pp	-11.4%+11.1pp	-22.5%+4.7pp	-27.2%+22.0pp	-49.2%-16.6pp	-32.6%-1.2pp	-31.4%

Similar Companies

Alphatec Hldgs Inc ATEC

$1.2B

Inspire Medical INSP

$1.3B

Quidel QDEL

$736.5M

Haemonetics Corp Mass HAE

$2.6B

Livanova Plc LIVN

$3.9B

Frequently Asked Questions

What is Procept Biorobotics Corp's annual revenue?

Procept Biorobotics Corp (PRCT) reported $308.1M in total revenue for fiscal year 2025. This represents a 37.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Procept Biorobotics Corp's revenue growing?

Procept Biorobotics Corp (PRCT) revenue grew by 37.2% year-over-year, from $224.5M to $308.1M in fiscal year 2025.

Is Procept Biorobotics Corp profitable?

No, Procept Biorobotics Corp (PRCT) reported a net income of -$96K in fiscal year 2025, with a net profit margin of -0.0%.

What is Procept Biorobotics Corp's EBITDA?

Procept Biorobotics Corp (PRCT) had EBITDA of -$97.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Procept Biorobotics Corp have?

As of fiscal year 2025, Procept Biorobotics Corp (PRCT) had $286.5M in cash and equivalents against $51.6M in long-term debt.

What is Procept Biorobotics Corp's gross margin?

Procept Biorobotics Corp (PRCT) had a gross margin of 63.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Procept Biorobotics Corp's operating margin?

Procept Biorobotics Corp (PRCT) had an operating margin of -33.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Procept Biorobotics Corp's net profit margin?

Procept Biorobotics Corp (PRCT) had a net profit margin of -0.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Procept Biorobotics Corp's return on equity (ROE)?

Procept Biorobotics Corp (PRCT) has a return on equity of -0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Procept Biorobotics Corp's free cash flow?

Procept Biorobotics Corp (PRCT) generated -$58.3M in free cash flow during fiscal year 2025. This represents a 43.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Procept Biorobotics Corp's operating cash flow?

Procept Biorobotics Corp (PRCT) generated -$49.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Procept Biorobotics Corp's total assets?

Procept Biorobotics Corp (PRCT) had $508.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Procept Biorobotics Corp's capital expenditures?

Procept Biorobotics Corp (PRCT) invested $9.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Procept Biorobotics Corp spend on research and development?

Procept Biorobotics Corp (PRCT) invested $71.3M in research and development during fiscal year 2025.

How many shares does Procept Biorobotics Corp have outstanding?

Procept Biorobotics Corp (PRCT) had 56M shares outstanding as of fiscal year 2025.

What is Procept Biorobotics Corp's current ratio?

Procept Biorobotics Corp (PRCT) had a current ratio of 6.85 as of fiscal year 2025, which is generally considered healthy.

What is Procept Biorobotics Corp's debt-to-equity ratio?

Procept Biorobotics Corp (PRCT) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Procept Biorobotics Corp's return on assets (ROA)?

Procept Biorobotics Corp (PRCT) had a return on assets of -0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Procept Biorobotics Corp's cash runway?

Based on fiscal year 2025 data, Procept Biorobotics Corp (PRCT) had $286.5M in cash against an annual operating cash burn of $49.0M. This gives an estimated cash runway of approximately 70 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Procept Biorobotics Corp's Piotroski F-Score?

Procept Biorobotics Corp (PRCT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Procept Biorobotics Corp's earnings high quality?

Procept Biorobotics Corp (PRCT) has an earnings quality ratio of 512.55x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Procept Biorobotics Corp cover its interest payments?

Procept Biorobotics Corp (PRCT) has an interest coverage ratio of -29.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Procept Biorobotics Corp?

Procept Biorobotics Corp (PRCT) scores 52 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.